Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EMD 72000: Phase I data; Phase II for ovarian cancer

In a Phase I trial, patients have received up to 800 mg of

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE